Lastly, the limited evidence on the effects of GLP-1 RAs on key pathognomonic proteins, Aβ and α-synuclein, weakens the scientific basis for considering GLP-1 RAs as major game-changers for neurodegenerative diseases. This evidence concerns the gene GCG and neurodegenerative disease.